

The background of the slide features a stylized DNA double helix structure. The left portion of the helix is rendered in orange and yellow tones, while the right portion is in blue. The helix is composed of spheres representing atoms, connected by lines. In the background, there are faint, semi-transparent line graphs and data points, suggesting a focus on scientific research and data analysis. The overall color palette is a mix of warm oranges and cool blues.

RennovaHealth

Solutions Driven By Innovation

Nasdaq: RNVA

Forward looking Statements and Non-GAAP Information

This presentation includes forward-looking statements about Rennova Health's anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations and strategy for the combined businesses, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Rennova Health with the Securities and Exchange Commission. Rennova Health undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances, except to the extent required by applicable law or regulation.

Note: This presentation includes certain "Non-GAAP" financial measures as defined by SEC rules. As required by the SEC, we have provided a reconciliation of those measures to the most directly comparable GAAP measures on the Regulation G slide included as slide 16 of this presentation. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, reported GAAP results.

RennovaHealth

Solutions Driven By Innovation

NASDAQ: RNVA

Listed on Nasdaq on November 3rd 2015
after completion of a merger between
Medytox Solutions, Inc. and CollabRx, Inc.



OTCBB since 2011 (MMMS)




Nasdaq listed since 1995
CollabRx since 2012 (CLRXX)

- We are four years into our business plan with a number of significant milestones already achieved
- We have revenue – Medytox had \$58 million of sales in 2014
- Our operations are profitable, with Medytox having positive adjusted EBITDA of \$18.2 million in 2014
- We operate in a sizable and established market place
- We have a capable management team
- We have a solid foundation from which we can grow

Rennova Health, Inc. is a vertically integrated company that provides industry leading Diagnostics and supportive software solutions to healthcare providers.

Rennova Health owns and operates five high-complexity CLIA and CAP certified laboratories strategically located across the U.S



Rennova Health, Inc. offers a single source solution for Medical Providers

The diagnostics sector has changed dramatically in the last few years

Medical providers need more than just diagnostics

They need:

Efficient and easy ordering and reporting

Electronic health records

Seamless integration

Revenue Cycle Management

Funding and financial solutions

Interpretation of diagnostics

Rennova products:

Medytox Advantage

Medical Mime

Clinlab

Medical Billing Services

Platinum Financial Solutions

CollabRx

Medical providers need an increasing number of integrated and interoperable solutions to enable their business to function

Our Brands

Our solutions can be stand alone or integrated

RennovaHealth
Solutions Driven By Innovation

 **MEDICALMIME**

 **CollabRx**TM
Raising the standard in cancer treatment

CLINLAB
ADVANCED MEDICAL SOFTWARE 

 **MedicalBillingChoices**
REVENUE CYCLE MANAGEMENT

Medytox
Solutions & Services For Medical Providers


 **PLATINUM
FINANCIAL**
S O L U T I O N S

RennovaHealth

Solutions Driven By Innovation

CollabRx enables efficient interpretation of diagnostics results into meaningful and useful information.

StableSpot™



StableSpot is a proprietary collection device that simplifies collection and transportation of a patient blood or urine sample.

Pain Management

Behavioral Health

Self Directed Testing*



DME*

POC Medical Devices*

Medytox Advantage is a proprietary ordering and reporting software used primarily to order lab tests, but expandable to enable individuals or physicians to order other items.

CollabRx™
Raising the standard in cancer treatment

Interpretation:
Making diagnostics data meaningful

Cancer

Pharmacogenomics*

Neurotransmitters*

Esoteric Testing*

Self Directed Tests*

MBC provides billing services for Medytox owned laboratories, Medytox customers, and other medical providers.

MedicalBillingChoices
REVENUE CYCLE MANAGEMENT
A MEDYTOX OWNED COMPANY

PLATINUM FINANCIAL SOLUTIONS
A Medytox Owned Company

PFS offers medical receivables financing to medical providers.

MEDICALMIME

A Medytox Owned Company

Behavioral Health EHR

Ambulatory EHR

Medytox
Solutions & Services For Medical Providers

CLINLAB
ADVANCED MEDICAL SOFTWARE
A Medytox Owned Company

Medytox owns and operates five clinical laboratories.

ClinLab provides a uniform and consistent Lab Information System to operate our clinical laboratories.

MedicalMime is a user-friendly and efficient EHR solution that can be integrated with the company's Lab and Billing services or other service providers a customer may use.

* In progress

Drug and Alcohol Rehabilitation

- Total Market Size – estimated at \$35 Billion*
 - Large and growing number of facilities in a fragmented market
 - Between 14,500 to 16,700 outpatient clinics*
- Market growth from high demand:
 - Over 23 million Americans are addicted to alcohol and other drugs**
 - The number of Americans in addiction treatment ranges from 2.5 million to 4.1 million***
 - 3 to 5 million people who have a diagnostic addiction disorder warranting treatment will gain coverage through healthcare reform****

Pain Management Sector

- Total Market Size – estimated at \$2-\$4 billion*****
- Large and growing number of clinics in a fragmented market
 - Private clinics in the U.S. estimated between 1,500 to 2,500
 - More than 6,800 doctors specialize in pain management and more than 600,000 doctors are licensed to prescribe pain medication
- Market growth from high demand:
 - Chronic pain affects an estimated 100 million Americans, or one-third of the U.S. population*****
Approximately 25 million people experience moderate to severe chronic pain with significant pain-related activity limitations and diminished quality of life*****
 - Between 5 to 8 million people use opioids for long-term pain management
 - In 2012, U.S. providers wrote 259 million prescriptions for opioid painkillers*****

Market Drivers

Lab Services Drivers

- Secular growth
- Compliance

Value-added services

- Efficiency
- Cost
- Revenue cycle management

Sources:

*IBIS World,

**The National Council on Alcoholism and Drug
Dependency,

***SAMHSA,

****National Association of Alcoholism and Drug
Abuse Counselors

*****The U.S. Addiction Rehab Market, Bharat
Publication,


*****NIH,

*****CDC and Pain Physician Publication.



History

Pre-merger numbers
from Medytox




2015 Revenue 9 months: \$42.6M

Diagnostics represents >95% of our revenue

Transition year

- Investment in Labs
- Investment in software
- Merger costs
- Billing Company restructure
- Toxicology sector
 - Additional scrutiny by payers and slower payments caused by many Labs who had adopted fraudulent practices

Overhead, merger and investment costs will outweigh profit from operations for 2015



Capital Structure

13,763,275 common shares outstanding as of 11/19/2015

Preference Shares

5,000 shares of Series B Preference shares

These shares convert to 1,146,789 additional shares of common stock on Dec 31st each year for five years

Total = 5,733,945 additional common shares over five years

\$360,000 of convertible preferred shares from an acquisition that will convert to common stock before Sept 2016

Warrants 446,947 warrants to purchase shares at \$9.40

Options	\$4.80	467,000
	\$5.00	7,800,000
	\$6.11	970,800
	\$7.50	18,467
	\$9.40	446,947
	\$9.77	325,600
	\$10.00	7,000,000
	\$10.50	1,250
	\$15.00	1,000
	\$19.90	8,658
	>\$20	29,900

**Fully diluted
(if all options are exercised)
\$22M**

at \$5.00 is estimated 27M Debt of approximately \$6M

at \$10.00 is estimated 34M

Receivables of approximately

(Medytox at November 25th 2015)

Management:

- **Seamus Lagan** **CEO**
20 years experience in the restructuring, development and management of startup and small companies
- **Jason Adams** **CFO**
CFO in behavioral health sector and Senior Financial Management of public companies
- **Sebastien Sainsbury** **Investor Relations**
Banking and wealth management and 10 years on the Board of AIG International
- **Steven Burdelski** **Chief Compliance Officer**
25 years with the FBI with responsibility for corporate and legal compliance to improve performance
- **Frank Dias** **Business Development and Sales**
Entrepreneur with 25 years experience in sales and logistics
- **Tiffany Vandemark** **Marketing Director**
15 years in marketing. Oversaw the launch and first four years of Chobani (Greek yogurt)
- **Dr. William DePond** **COO of Lab Operations and CEO of each Lab**
Board certified in Anatomic and Clinical Pathology with 2 years in management at Quest Diagnostics
- **Dean Viskovich** **In-House counsel**
25 years experience as a trial and defense attorney in the healthcare sector
- **Charles Darcy** **Compliance Officer**
COO in hospitals with Bachelors degree in Laboratory Science and Masters degree in Health Administration

Board:

- **Thomas Mika** Chairman of Rennova, CEO of CollabRx (subsidiary)
10 years as Chairman and CEO of a Nasdaq listed Company. Oversaw a number of public offerings. Holds a Bachelor of Science degree in Microbiology, MBA Harvard
- **Seamus Lagan** CEO
20 years experience in the restructuring, development and management of startup and small companies. Founder, investor and largest shareholder in what is now Rennova
- **Christopher Diamantis** Director
Chairman and CEO of Integrated Financial Settlements, Inc., a structured settlement consulting firm. Acts as Chairman and a director of a number of Banks
- **Michael Goldberg** Director
16 years as CEO of an AMEX-listed healthcare company that acquired 23 labs and 2 hospitals under his tenure
- **Dr. Paul Billings** Director
A nationally recognized expert on genomic and precision medicine. Has served as Chief Medical Officer or Director of some of the nation's largest health care companies
- **Benjamin Frank** Director
Retired lawyer and businessman who served as Chairman of the Board of the Healthcare District of Palm Beach County
- **Robert Lee** Director
16 years as a Managing Director of Morgan Stanley Dean Witter and Managing Director of the M&A group at Morgan Stanley, where he worked closely with financial sponsors. Chairman of numerous audit committees

Foundation to grow from

...we are able to grow our core diagnostics business from a position of strength and to expand into the more complex, higher-margin clinical diagnostics

... we can aggressively acquire the customers, licenses or business of cash-strapped, failing diagnostic labs of all sizes

...our expertise allows us to identify and vet prospects for the quality and integrity of their licenses, payor relationships, receivables and customers

...our information technology solutions allow for seamless integration of customer or company acquisitions, to improve efficiency, and to exercise continuous control

...our unblemished record for compliance in all aspects of our business will attract the best of customers, companies and partners

Current focus

Expand our current lab business accross the nation	Ongoing
Capitalize on the disruption in the toxicology industry	Ongoing
Add additional tests and methodologies to our menu	Ongoing
Roll out our EHR product	Launched Oct
Roll out our Medical Billing Services	Launch underway
Implement our Financial services solution	Next 12 months
Infrastructure	
Analytics	

Current projects

Self directed testing	In progress
Collection solution	1st half of 2016
Added value interpretation	1st half of 2016
Cancer diagnostics	1st half of 2017
Epinephrine	
Point of care test for Diabetes	2 year project

Reconciliation of GAAP to Adjusted Measures - Medytox Solutions, Inc. Pre Merger

<i>(in thousands)</i>	2011	2012	2013	2014	Jan-Sep 2015
Net Revenue	\$ 3,993	\$ 21,076	\$ 41,889	\$ 57,928	\$ 28,921
Write-off of receivables aged greater than one year	-	-	-	-	13,299
Adjusted Revenue	\$ 3,993	\$ 21,076	\$ 41,889	\$ 57,928	\$ 42,220
Net Income	\$ 587	\$ 2,747	\$ 7,820	\$ 8,260	\$ (7,079)
Provision for Income Taxes	(172)	481	5,569	7,561	(2,580)
Interest Expense	175	654	475	514	1,595
Depreciation and Amortization	18	66	408	1,500	1,979
EBITDA	608	3,948	14,272	17,835	(6,085)
Write-off of receivables aged greater than one year	-	-	-	-	13,299
Stock Compensation Expense	13	235	63	343	3,381
Merger, Acquisition and Integration Costs	-	-	-	-	925
Adjusted EBITDA	\$ 621	\$ 4,183	\$ 14,335	\$ 18,178	\$ 11,520

Contact Us

Rennova Health, Inc.
400 South Australian Avenue
8th Floor
West Palm Beach, FL 33401

Phone: 844-RENNOVA

Email: info@rennovahealth.com
www.rennovahealth.com